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Key Points: 
 
• Hematopoietic stem cell transplantation (HSCT) represents an effective and definitive 
treatment for DADA2. 
• HSCT can cure the immunological, hematological, and vascular phenotype of DADA2 
with 100% survival at median follow-up of 18 months. 
 
 
 
Abstract 
 
Deficiency of adenosine deaminase 2 (DADA2) is caused by biallelic deleterious mutations in 
CECR1. DADA2 results in variable autoinflammation and vasculopathy (recurrent fevers, 
livedo reticularis, polyarteritis nodosa, lacunar ischemic strokes and intracranial 
hemorrhages), immunodeficiency and bone marrow failure. TNF-α blockade is the treatment 
of choice for the autoinflammation and vascular manifestations. Hematopoietic stem cell 
transplantation (HSCT) represents a potential definitive treatment. We present a cohort of 14 
patients from 6 countries who received HSCT for DADA2. Indication for HSCT was bone 
marrow dysfunction or immunodeficiency. Six of 14 patients had vasculitis pre-HSCT. The 
median age at HSCT was 7.5 years. Conditioning regimens were myeloablative (9), and 
reduced intensity (5). Donors were HLA-matched sibling (n=1), HLA-matched unrelated 
(n=9), HLA-mismatched unrelated (n=3), and HLA haploidentical sibling (n=1). All patients 
are alive and well with no new vascular events and resolution of hematological and 
immunological phenotype at a median follow-up of 18mo (range 5mo to 13yr). Plasma ADA2 
enzyme activity normalized in those tested post-HSCT (7/7), as early as D+14 (myeloid 
engraftment). Post-HSCT hematological autoimmunity (cytopenias) was reported in 4 
patients, acute graft versus host disease (GvHD) grade 1 in 2, grade 2 in 3 and grade 3-4 in 
1, and moderate chronic GvHD in 1 patient. In conclusion, in 14 patients, HSCT was an 
effective and definitive treatment for DADA2.  
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Introduction 
 
In 2014, two independent studies reported biallelic deleterious mutations in the cat eye 
chromosome region 1 gene (CECR1), encoding adenosine deaminase 2 (ADA2), as the 
cause of a new and rare auto-inflammatory condition, named human deficiency of ADA2 
syndrome (DADA2) (OMIM # 615688).1,2 In the initial reports, DADA2 was hallmarked by 
recurrent episodes of fever with elevation of acute phase reactants and vasculopathy ranging 
from early-onset cutaneous livedo reticularis, Raynaud’s phenomenon and polyarteritis to life-
threatening intracranial vasculopathy with lacunar strokes and hemorrhages.3,4 Bone marrow 
dysfunction, which may include pure red cell aplasia (PRCA), Diamond-Blackfan like anemia, 
thrombocytopenia and neutropenia, is now recognized as an equally important 
manifestation.5,6 In addition, immunodeficiency can be found with hypogammaglobulinemia 
(esp. IgM) as well as disturbances in the T cell compartment.7 Inflammatory bowel disease, 
reminiscent of the bowel involvement found in patients with common variable 
immunodeficiency (devoid of plasma cells) can also be found. Eight of the nearly 100 DADA2 
patients (8%) reported to date in the literature are deceased.1,2,8,9 The most common reason 
of death was stroke (in 4/8 patients). The diagnosis of DADA2 is based on the measurement 
of low/absent plasma ADA2 enzymatic activity and on the identification of biallelic loss-of-
function mutations in CECR1, which is located within chromosome 22q11. Patients with 
homozygous deletions encompassing the CECR1 locus on 22q11 show the same phenotype. 
Also, absent plasma ADA2 enzymatic activity has been described in singular patients with 
monoallelic mutations in CECR1. It is unclear at this point whether in these cases a second 
(cryptic) mutation is present on the other allele, in an intron, in the promoter region, or rather 
in a different gene affecting ADA2 expression. Alternatively copy number variations affecting 
the CECR1 locus may have been missed. 
 
In humans, two ADA proteins have been described: ADA1 and ADA2. Deficiency of ADA1, 
encoded by the ADA gene on chromosome 20q, causes severe combined immunodeficiency 
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owing to profound depletion of T, B, and NK lymphocytes, which normally show high 
expression of ADA1. In these patients, plasma levels of adenosine and deoxyadenosine are 
elevated, and their red cells show a marked accumulation of dATP (derived from 
deoxyadenosine). Lymphopenia has been attributed primarily to dATP pool expansion, which 
blocks DNA synthesis and induces apoptosis in immature lymphoid cells. Aberrant signalling 
via receptors for adenosine may contribute to non-immunologic features that occur in some 
ADA1-deficient patients. In contrast to ADA1, ADA2 is primarily expressed by myeloid cells 
and is mainly secreted in plasma by monocytes.10 The function of ADA2 in cellular pathways 
is still enigmatic and its absence in mice has hampered investigation of pathogenic 
mechanisms. However, where studied, the levels of adenosine and deoxyadenosine in 
plasma, and of dATP in red cells, have not been elevated in DADA2.1,2 It has been postulated 
that ADA2 is an adenosine deaminase related growth factor.11 In vitro studies suggest that 
ADA2 secreted from monocytes, acts as an autocrine factor to stimulate their differentiation 
into macrophages and dendritic cells.12 ADA2 may play a role in maintaining the balance 
between M1 and M2 macrophages with ADA2 deficiency leading to an M1 proinflammatory 
phenotype as reviewed by Martinon and Aksentijevich.13 A mixed neutrophil and type I 
interferon signature was observed in two ADA2 deficient patients.14 This correlated with 
increased levels of proinflammatory cytokines such as IL-6 in the plasma of ADA2 deficient 
patients in two studies and with the vasculitis seen in patients with DADA2. Despite CECR1 
not being expressed in the endothelium, deficiency of ADA2 leads to endothelial instability as 
also shown in the zebrafish model and in co-culture systems of endothelial cells.1,2  
 
Medical management of patients with DADA2 is challenging. None of the commonly used 
immunosuppressive drugs have been particularly effective in controlling disease 
manifestations. Etanercept in particular or anti-TNF agents have shown promise in the 
management of the inflammatory syndrome and vasculitis.7,15 However, at least etanercept 
does not appear to reverse the hematological phenotype (Polina Stepensky, unpublished 
observation, n=5). Soon after the first description of DADA2, hematopoietic stem cell 
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transplantation (HSCT) was reported to result in a rapid and sustained immune reconstitution 
and resolution of the systemic inflammation.16,17 Indeed, given that monocytes are the main 
cellular source for ADA2, there is a strong rationale for HSCT as a potential cure. Additional 
patient case reports have since confirmed these findings.6,18–20 The aim of the present study 
is to better define the role for HSCT as a potential cure for DADA2. We report the results of a 
multinational cohort study of 14 patients with proven DADA2 who underwent HSCT, including 
the previously reported cases. All are alive, well and cured. 
 
Patients and Methods 
We conducted an international cohort study on patients with DADA2 via the European Group 
for Blood and Marrow Transplantation (EBMT), European Society for Immunodeficiencies 
(ESID), Primary Immunodeficiency Transplant Consortium (PIDTC), and Center for 
International Blood and Marrow Transplant Research (CIBMTR). Data collection started after 
the Inaugural International Conference on Deficiency of ADA2 hosted by the DADA2 
Foundation and held in Bethesda, Maryland on November 11th, 2016. Criteria for patient 
inclusion into the study were: 1) diagnostic findings consistent with DADA2 and confirmed by 
genetic testing and/or 2) diagnostic findings consistent with DADA2 and absent plasma ADA2 
activity, and 3) HSCT performed with a follow-up time more than 5 months after HSCT. A 
questionnaire was completed by participating physicians. Data were obtained in accordance 
with the Declaration of Helsinki. All patients or their guardians had given written informed 
consent for data collection. The study was approved by the Ethical Committee of the 
University Hospitals Leuven. Neutrophil engraftment was defined as the first of 3 consecutive 
days when the absolute neutrophil count was ≥ 0.5 x 109/L, platelet engraftment defined as 
the first of 7 days without a platelet transfusion that the platelet count was ≥ 20 x 109/L, and 
full donor chimerism was defined as ≥ 95% of leukocytes being of donor origin in peripheral 
blood or bone marrow samples. The diagnosis and grading of acute and chronic GvHD were 
defined according to international standard criteria. 
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Results 
We received complete data sets for 14 DADA2 patients transplanted between 2000-2016. 
Patients received treatment in 11 different centers in 6 countries in Europe and North 
America. Five patients were reported previously.16–21 The male/female ratio was 8/6. The 
median age at initial presentation was 1.5 years (range birth to 16 years). The median age at 
genetic diagnosis was 10 years (range 2-25 years) (Table 1). The diagnosis of DADA2 was 
confirmed at the molecular level by demonstration of biallelic deleterious CECR1 mutations in 
all patients. Plasma ADA2 enzyme activity prior to HSCT was low in 6/6 patients tested 
(Table 2). Six of 14 patients had vasculitis prior to HSCT, 3 of whom had intracranial 
hemorrhage. All patients except one had received at least one line of immunosuppressive 
treatment prior to HSCT. Hematological manifestations were prominent in this cohort with 
PRCA documented in 7/14 patients, neutropenia in 6/14, immune mediated 
thrombocytopenia (ITP) in 2/14 and pancytopenia in 3/14 at presentation. Low IgG was 
present in 7/10, low IgA was present in 7/10 and low IgM in 7/10 measured. Seven of 14 
patients had recurrent infections, of whom 3/7 especially viral infections. Ten of 14 patients 
were on immunoglobulin substitution prior to HSCT and only 2 continue to require 
replacement post HSCT (both less than a year from HSCT). Splenomegaly was present in 
11/14 patients. 
 
The median age at HSCT was 7.5 years (range 2-23 years). Overall survival of patients 
undergoing HSCT was 100% (14/14 patients alive). Six of 14 patients had received HSCT 
prior to description of the condition in 2014. Indications for HSCT were bone marrow 
dysfunction (neutropenia, pure red cell aplasia (PRCA), thrombocytopenia), and/or 
immunodeficiency (hypogammaglobulinemia with recurrent infections) (Table 3). A total of 20 
HSCT procedures were performed for 14 patients: two patients required a second transplant 
for engraftment failure due to use of an apparently healthy sibling donors, who later were 
discovered to carry the deleterious CECR1 mutations and be ADA2 deficient. They received 
salvage HSCT from matched unrelated donors. One patient required a second HSCT for graft 
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failure. Another patient required a boost due to insufficient stem cell dose at first transplant.  
Yet another patient originally received myeloablative conditioning but required two 
unconditioned boosts following a drop in whole blood chimerism to 30%. This coincided with 
a decline of plasma ADA2 enzyme activity to pretransplant levels and a new presentation of 
auto-immune PRCA followed by agranulocytosis. Regimens were different across transplant 
centers. Nine patients received myeloablative conditioning and 5 received a reduced intensity 
regimen. The most commonly used regimen (in 5 patients) was treosulfan/fludarabine +/- 
thiotepa with ATG or alemtuzumab. Serotherapy was used in 12/14 patients: ATG in 4 and 
alemtuzumab in 8 patients. Bone marrow was the source of stem cells in 10 grafts, peripheral 
blood stem cells in 4. Donors were matched sibling (n=1), haplo-identical sibling (n=1), 10/10 
matched unrelated (n=9), and mismatched unrelated (n=3) for the final curative transplant 
procedures. Methotrexate associated with a calcineurin inhibitor was the prophylactic regimen 
for graft-versus-host-disease in 9/14 patients (Table 3). All patients received antimicrobial 
and graft versus host disease (GvHD) prophylaxis as per discretion of the transplant 
physician/center. 
 
All patients engrafted at a median of day +20 for neutrophils and at day +23 for platelets. All 
patients are alive and well with a median follow-up of 18 months (range 5m-13y). All patients 
had resolution of the hematological and immunological phenotype and no further vascular 
events were reported in 13/14 patients (Figure 1). One patient suffered from a pineal gland 
hemorrhage immediately post-HSCT at the time of prolonged thrombocytopenia as described 
earlier.18 He has had no further vascular events since with a follow-up of 76 months. 
Chimerism analysis showed full donor white blood cell chimerism in all patients. ADA2 
plasma enzyme activity normalized in all patients in whom ADA2 activity was monitored post-
HSCT (n=7) (Table 2). This occurred as early as 14 days post-HSCT, concurring with 
monocyte reappearance in the peripheral blood as verified by prospective monitoring of 
plasma ADA2 enzyme activity in 1 patient (Isabelle Meyts, unpublished observation). As for 
HSCT related morbidity: two patients developed veno-occlusive disease, which responded to 
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fluid restriction. Acute GvHD developed in 6/14 and resolved after standard treatment. 
Moderate chronic GvHD developed in only one patient. Viral reactivation was a frequent 
complication post-HSCT as it occurred in 10/14 patients. Adenoviremia was the most 
common in 6/14 patients (42%). The patients who developed more than 2 viral reactivations 
all received peripheral blood stem cells. Post-HSCT hematological autoimmune phenomena 
were reported in 4 of 14 patients: ITP in 2, auto-immune hemolytic anemia (AIHA) in 1 and 
neutropenia with immune mediated PRCA in 1, responding to various treatment regimens 
(high dose IVIG / steroids / sirolimus / rituximab / bortezomib / Romiplostim). Alopecia as a 
feature of DADA2 was present in 1 patient and completely resolved post-HSCT.  
Discussion 
We report the results of the first international survey on the outcome of HSCT for DADA2. 
The results support the use of HSCT as a definitive cure for DADA2 with 14 out of 14 patients 
alive and well and 12/14 patients off all treatment at a median time post-HSCT of 18 months. 
Two patients are still on immunosuppression as both are less than a year out of HSCT. HSCT 
proved curative for the hematological, immunological as well as vascular phenotype 
associated with the condition. Although the number of patients reported here is too limited to 
issue a general recommendation for HSCT in DADA2, the data clearly support the feasibility 
of HSCT as a definitive treatment option.  
 
Importantly for all the DADA2 patients described here the indication for HSCT was the 
hematological and/or immunological disorder, whereas the disease emphasis in the initial 
reports was on the vasculopathy with livedo, polyarteritis and lacunar infarction. Indeed, 
PRCA, severe neutropenia, and refractory thrombocytopenia as well as combined 
immunodeficiency (including recurrent infection with herpesviridae) prevailed in all 
transplanted patients. Prior to HSCT, treatment with TNF inhibitors (etanercept, infliximab) 
was attempted, but proved unsuccessful in 4 patients, and interleukin-1 receptor antagonist 
(anakinra) failed in 2 patients as far as restoration of the hematological and immunological 
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phenotype was concerned. HSCT not only resolved the hematological and immunological 
phenotype, it also resulted in resolution of the vascular phenotype in all 6 patients who had 
vasculitis prior to HSCT. Only one patient experienced a single vascular event early post-
HSCT at the time of severe thrombocytopenia. The same patient had an episode of late VOD, 
which responded to fluid restriction. No further vascular events were reported in any of the 
transplanted patients, in line with the current notion that the basic pathophysiology lies in 
macrophage skewing towards an M1 proinflammatory phenotype and that the vasculopathy 
phenotype can also be cured by HSCT. In this limited number of patients, no genotype-
phenotype correlation could be found. Therefore, the mere presence of a given mutation 
alone cannot support the decision to proceed to HSCT for this rare condition; rather the 
phenotype should be weighed in the decision to proceed to HSCT or to provide conventional 
treatment.  
 
As becomes clear from our data, donor selection is important. Prior to the unravelling of the 
genetics of the disease, two patients received a graft from apparently healthy sibling donors 
who later, were shown to carry disease causing CECR1 mutations and to be ADA2 deficient, 
resulting in engraftment failure. The question of whether a sibling donor who carries a single 
deleterious mutation in CECR1 is a good option remains unclear at present. However, it can 
be considered safer to opt for a matched unrelated donor in these cases given that a drop in 
chimerism in 1 patient resulted in PRCA. Moreover at present, since absent ADA2 activity 
has been reported in patients with monoallelic CECR1 mutations, haplo-insufficiency of 
CECR1 cannot be excluded as a cause for minor disease manifestations. Because recipient 
cells may have impaired ability to reject graft hematopoietic cells, and because in cases of 
immunodeficiency, donor lymphocytes could have survival advantage over ADA2-deficient 
recipient cells, non-myeloablative conditioning can be a reasonable option as shown in some 
of the reported patients. In addition, a reduced intensity-conditioning (RIC) regimen may be a 
reasonable option until there is a better understanding of what degree of donor is necessary 
to cure the disease.  
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Infectious viral complications were frequent in our cohort, although they did not result in 
mortality. Adenovirus reactivation was the most common viral complication present in 6/14 
patients (42%). This goes with previously published reports 22,23. Thus, frequent prospective 
monitoring of patients, and pre-emptive treatment is essential.  
 
Importantly, post-HSCT hematologic autoimmune complications were common in our cohort 
(ITP, PRCA, AIHA, neutropenia), seen in 4/14 patients (28%). Previous reports suggested the 
association of post-HSCT autoimmune hematologic disorders with non-malignant disorders, 
unrelated donors, serotherapy, and younger age at HSCT.24–26 In our cohort, the association 
with serotherapy, in particular alemtuzumab, and younger age at HSCT might represent a 
potential explanation. However, at present we have no solid explanation for the auto-immune 
phenomena post-HSCT. 
 
In conclusion, we report the successful treatment by HSCT in 14 DADA2 patients. All patients 
are alive and well and cured of immunological, hematological, and vascular manifestations. 
Thus, HSCT is an effective treatment option for definitive treatment of DADA2. Given the 
important morbidity and potential mortality associated with this disease, HSCT can be 
envisaged in any patient with DADA2 and severe immunological or hematological 
manifestations or even vasculopathy unresponsive to anti-inflammatory treatment. A matched 
unrelated donor can be considered in cases where there is no unaffected matched sibling 
donor.  
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Table 1: Demographic and clinical features of the 14 DADA2 patients before HSCT 
Patient ID 
 
Gender/Ethnicity 
 
Age at 
disease 
onset (y) 
Age at 
genetic 
diagnosis (y) 
DADA2 clinical manifestations 
 
CD4, CD8, CD19, CD56 
(n x 10*6/L) 
IgG 
 
IgA 
(mg/dl) 
IgM 
 
Previous treatment 
 
Reference 
P001 M, Caucasian 3 4 
PRCA, HSM, alopecia, strabismus, 
recurrent fevers, aphthous ulcers 
814, 459, 104, 60 605 40 < 6 
Prednisone, MMF, 
Sirolimus, CsA 
6,21 
P002 F, Hispanic 7 21 Recurrent infections, ID 361, 262, 0, 32 NA NA NA Prednisone 
20 
P003 F, Caucasian 7 11 Splenomegaly, ICH, livedo, arthritis 528, 211, 26, 30 NA NA NA Infliximab 
 
P004 F, Caucasian 1 9 
Pancytopenia, stroke, ICH, vasculitis, 
arthritis, HSM, HTN, CMP, ID 
273, 222, 23, 29 354 34 9 
Prednisone, Etanercept, 
Anakinra, Azathioprine 
19 
P005 M, Caucasian 0 2 PRCA, LNP, HSM, recurrent infections 1763, 1037, 415, 104 426 <8 < 6 Prednisone 
 
P006 F, Caucasian 14 15 PRCA, neutropenia 441, 276, 43, 35 499 11 15 Prednisone 
 
P007 M, Caucasian 0.5 13 
PRCA, neutropenia, SAA, HSM, livedo, 
IDDM, GHD 
NA 360 60 30 None 
17 
P008
* 
M, Caucasian 0.5 5 
PRCA, pancytopenia, splenomegaly, 
recurrent infections, LNP 
653, 93, 11, 0.5 997 2.4 7 
Prednisone, Sirolimus, 
Tacrolimus 
16, 18 
P009
* 
M, Caucasian 0.4 4 
Anemia, neutropenia, HSM, LNP, IBD, 
SAH, TIA, recurrent infections 
599, 278, 228, 147 436 17 54 
Prednisone, Azathioprine, 
Sirolimus, Etanercept 
 
P010 M, Caucasian 2 22 
Anemia, lymphopenia, HSM, Livedo, 
ICH, HTN, optic nerve atrophy, PAN 
50, 50, 1, 10 465 47 17 
Prednisone, Azathioprine, 
Infliximab 
 
P011 F, Caucasian 2.5 4 
PRCA, Vasculitis, pancytopenia, 
epilepsy, HSM, aphthous ulcers 
386, 257, 237, 41 1000 2.4 74 Prednisone 
 
P012 F, Caucasian 16 25 
ITP, HSM, lymphoproliferation, 
recurrent infections, lung granuloma 
1670, 1721, 106, 101 NA NA NA Prednisone, ATG 
 
P013 M, Caucasian 0.3 9 
PRCA, neutropenia, splenomegaly, 
IBD, recurrent fevers, aphthous ulcers 
607, 781, 685, 90 290 119 9 Prednisone, Anakinra 
 
P014 M, Hispanic 0 18 PRCA, hepatopathy, aphthous ulcers NA NA NA NA Prednisone 
 
 
*: Siblings; Bold font indicates low values for age. Y: year; M: male; F: female; HSM: hepatosplenomegaly; URI: upper respiratory infection; ID: 
immunodeficiency; ICH: intracranial hemorrhage; HTN: hypertension; CMP: cardiomyopathy; PRCA: pure red cell aplasia; LNP: lymphadenopathy; GHD: 
growth hormone deficiency; IDDM: insulin dependent diabetes mellitus; IBD: inflammatory bowel disease; SAH: subarachnoid hemorrhage; TIA: transient 
ischemic attack; PAN: polyarteritis nodosa; ATG: antithymocyte globulin. 
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Table 2: Genetic and Biochemical Basis for Diagnosis of the 14 DADA2 patients  
 
Patient ID 
 
CECR1 allele 1 CECR1 allele 2 ADA2 activity 
pre HSCT 
 ADA2 activity 
post HSCT 
 
P001 c.1110C>A (p.N370K)  c.1072G>A (p.G358R) 0.6
a 
 19.7
a
 at 1y 
 
P002 c.794C>G (p.S265X)  c.794C>G (p.S265X) 0.0
a 
 
10.8
a
 at 1y 
 
P003 c.660C>A (p.Y220X) c.660C>A (p.Y220X) 2.5
b 
 
NA 
 
P004 c.506G>A (p.R169Q) c.506G>A (p.R169Q) 0.8
a 
 
7.0
a
 at 1y 
 
P005
 
c.144delG (p.R49fs)  c.506G>A (p.R169Q) NA 
 
NA 
 
P006
 
c.144dupG (p.R49fs) c.506G>A (p.R169Q) NA 
 
NA 
 
P007 c.506G>A (p.R169Q) c.506G>A (p.R169Q) NA 
 
15.3
a
 at 3m 
 
P008
* 
c.506G>A (p.R169Q) c.506G>A (p.R169Q) NA 
 
22.07
a 
 
P009
* 
c.506G>A (p.R169Q) c.506G>A (p.R169Q) 0.11
a 
 
NA 
 
P010 c.506C>T (p.R169Q) c.2T>C (p.M1T) NA 
 
NA 
 
P011 c.506G>A (p.R169Q) c.506G>A (p.R169Q) NA
 
 
NA 
 
P012 c.140G>T (p.G47V)  c.336C>G (p.H112Q) NA 
 
NA 
 
P013 c.144del (p.R49fs)  c.47+2T>C (splice site) 0.2
a 
 
11.7
a 
 
P014 c.506G>A (p.R169Q)  c.1072G>A (p.G358R) NA 
 
22.3
a 
 
 
*: Siblings 
a) Plasma ADA2 (mU per mL): Healthy controls (n=20 + pooled normal plasma), 14.2 ± 5.2 (4.8 - 27.2). DADA2 patients (n=25), 0.4 ± 0.5 (0.02 - 1.7).  
b) Dried Plasma Spots ADA2 (mU/g protein): Healthy controls (n=39), 130.5 ± 49.8 (58 - 271). DADA2 patients (n=40), 4.4 ± 4.3 (0.04 -17.2) 
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Table 3: Transplant data and post-HSCT complications for the 14 DADA2 patients 
Patient ID 
 
Year of 
HSCT 
Age at HCT 
(y)/Gender 
Indication of 
HSCT 
HLA match/graft 
source 
Conditioning  
 
GvHD 
prophylaxis 
 
aGvHD/
grade 
cGvHD 
 
Viral comp Autoimmune 
comp 
Last 
chimerism 
Last 
follow 
up (m) 
P001 2016 4/M 
PRCA, 
neutropenia 
10/10 MUD BM 
Flu/Mel/Alem 
(RIC) 
MTX/Tacrolimus No No EBV/HHV6 ITP 1y 98% 14 
P002 2013 20/F Neutropenia 
5/10 Haplo BM 
(Boost for low CD34 
dose- 0.5x10
6
/kg) 
Flu/Bu/Cy/TBI200 Tacro/MMF/PTCy No No None None 3y 100% 41 
P003 2016 11/F 
Pancytopenia 
Autoimmunity 
10/10 MUD PB Flu/Treo/TT/ATG MTX/CsA 
Skin 
grade 1 
No 
Adeno/HHV6, 
BK 
None 6m 100% 12 
P004 2012 8/F Pancytopenia 9/10 MMUD BM Flu/Treo/Alem MTX/CsA No No Adeno/VZV None 5y 100% 60 
P005 2016 2/M 
PRCA, recurrent 
CMV 
10/10 MUD BM Flu/Treo/TT/ATG MTX/CsA 
Skin 
grade 2 
No Adeno None 6m 100% 12 
P006 2016 16/F 
PRCA, 
neutropenia 
9/10 MMUD PB 
(Second HSCT due to 
GF) 
Flu/TT/ATG  
(RIC) 
MTX/CsA No No BK/CMV None 1m 100% 4 
P007 2003 4/M Refractory SAA 
10/10 MUD BM 
(First HSCT from 
affected MSD) 
Flu/TBI/Alem 
(RIC) 
MTX/CsA No No Adeno None 3y 100% 161 
P008
* 
2009 3/M 
PRCA, 
neutropenia 
MSD BM Bu/Cy MMF/CsA 
Colon 
grade 3-4 
No VZV ITP 3y >95% 76 
P009
* 
2016 5/M 
Recurrent TIA, 
immunodeficiency 
10/10 MUD PB 
(2 boosts for 
declining chimerism) 
Flu/Treo/Alem MMF/CsA 
Skin 
grade 1 
No 
Adeno/HSV1/
BK 
PRCA, 
neutropenia 
1y >95% 15 
P010 2016 23/M 
Severe 
lymphopenia, 
hypogamm 
10/10 MUD BM Flu/Bu/Alem MTX/CsA No No None None 6m >95% 11 
P011 2016 5/F 
PRCA, 
neutropenia 
10/10 MUD BM Flu/Treo/TT/Alem MMF/CsA 
Skin 
grade 1 
No CMV, EBV None 6m 100% 10 
P012 2014 23/F 
Severe 
neutropenia 
10/10 MUD BM 
Flu/Mel/Alem 
(RIC) 
Prednisone/CsA No No None None 2y 98% 39 
P013 2015 7/M PRCA 10/10 MUD BM Bu/Cy/ATG MTX/CsA No No None None 1y 100% 21 
P014 2007 9/M PRCA 
MMUD PB  
(First HSCT from 
affected MSD) 
Flu/TBI450/Alem 
(RIC) 
MTX/CsA 
Skin 
grade 2 
Skin +liver 
moderate 
CMV/adeno/ 
BK 
AIHA 3y 95% 117 
 
 
*: Siblings; GvHD: graft versus host disease; comp: complications; m: month; y: year; HSCT: hematopoietic stem cell transplant; MSD: matched sibling donor; 
MUD: matched unrelated donor; MMUD: mismatched unrelated donor; BM: bone marrow; PB: peripheral blood; Flu: fludarabine; Mel: melphalan; Alem: 
alemtuzumab; ATG: antithymocyte globulin; MTX: methotrexate; MMF: mycophenolate mofetil; CsA: cyclosporine A; Treo: treosulfan; TT: thiotepa; Bu: 
busulfan; Cy: cyclophosphamide; AIHA: autoimmune hemolytic anemia; Adeno: adenovirus.
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Figure Legends:  
Figure 1: Effect of HSCT in clinical features resolution. Dark grey squares represent the 
presence of a clinical feature/phenotype. Light grey squares represent major improvement in 
clinical features. White squares represent complete resolution of clinical feature. Each patient 
is presented by two attached columns (before and after transplant) for comparison. Follow-up 
time post-HSCT for each patient is shown in months in first row. Severe infections represent 
any viral, bacterial, or fungal infection that required antiviral, or antifungal treatment, or led to 
sepsis. IBD: inflammatory bowel disease; FTT: failure to thrive. 
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